Literature DB >> 24179616

Presence of disease specific autoantibodies against liver sinusoidal cells in primary biliary cirrhosis.

Ourania Sfakianaki1, Maria Tzardi, Argyro Voumvouraki, Aikaterini Afgoustaki, Meri Koulentaki, Elias Kouroumalis.   

Abstract

AIM: To investigate the presence of autoantibodies directed against liver sinusoidal cells in primary biliary cirrhosis (PBC).
METHODS: Liver biopsies from 21 PBC patients were studied and compared with 12 liver biopsies from disease controls [3 patients with hepatitis B (HBV) virus, 3 patients with hepatitis C virus (HCV), 3 patients with non-alcoholic steatohepatitis and 3 patients with acute alcoholic hepatitis (AAH)]. As healthy controls, we used tissue specimens adjacent to metastatic liver adenocarcinoma. Normal serum was taken from staff members of the unit. The determination of the cell type targeted by autoantibodies present in the patients sera was performed by indirect immunofluorescence (IIF) analysis using paraffin-embedded liver sections as a substrate. Sera from homologous or heterologous PBC patients or sera from the disease control group were used as primary antibodies. The presence of autoantibodies was identified using confocal microscopy.
RESULTS: In total, 18/21 (85.7%) PBC patients exhibited positive staining in the sinusoidal cells, 10/21 (47.6%) in lymphocytes, 8/21 (38%) in cholangiocytes and 7/21 (33.3%) in hepatocytes, when homologous serum and fluorescein isothiocyanate-conjugated immunoglobulin type G (IgG) secondary antibody were used. PBC sections incubated with heterologous PBC serum showed reduced staining (20% for sinusoidal cells, 20% for lymphocytes, 20% for cholangiocytes and 13.3% for hepatocytes). When IgM immunoglobulin, instead of IgG, was used as secondary antibody, positive staining was observed in 75% of lymphocytes, 62.5% of cholangiocytes, 37.5% of hepatocytes and 50% of the sinusoidal cells with a much stronger staining intensity. No staining was observed when either normal or PBC sera were used as a primary antibody on liver sections from the disease control group. When PBC sera were incubated with healthy control sections, weak positive staining of cholangiocytes was observed in 3/21 (14.3%) PBC serum samples. Steatohepatitis serum on PBC sections gave a positive staining of some hepatocytes and lymphocytes but no staining on viral hepatitis sections. Incubation with HBV sera stained some hepatocytes, cholangiocytes and intra-sinusoidal or portal lymphocytes of PBC, HBV and AAH patients but not HCV patients.
CONCLUSION: In this study, for the first time in diseased liver tissue, we have demonstrated that a large proportion of PBC patients have disease specific autoantibodies against liver sinusoidal cells.

Entities:  

Keywords:  Autoantibodies; Cholangiocytes; Liver tissue; Primary biliary cirrhosis; Sinusoidal cells

Year:  2013        PMID: 24179616      PMCID: PMC3812459          DOI: 10.4254/wjh.v5.i10.568

Source DB:  PubMed          Journal:  World J Hepatol


  34 in total

Review 1.  Disease-specific autoantibodies in primary biliary cirrhosis.

Authors:  Dimitrios P Bogdanos; Lars Komorowski
Journal:  Clin Chim Acta       Date:  2010-12-23       Impact factor: 3.786

2.  Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis.

Authors:  J Van de Water; L B Gerson; L D Ferrell; J R Lake; R L Coppel; K P Batts; R H Wiesner; M E Gershwin
Journal:  Hepatology       Date:  1996-11       Impact factor: 17.425

Review 3.  Autoantibodies against "nuclear dots" in primary biliary cirrhosis.

Authors:  C Szostecki; H H Guldner; H Will
Journal:  Semin Liver Dis       Date:  1997-02       Impact factor: 6.115

4.  In situ nucleic acid detection of PDC-E2, BCOADC-E2, OGDC-E2, PDC-E1alpha, BCOADC-E1alpha, OGDC-E1, and the E3 binding protein (protein X) in primary biliary cirrhosis.

Authors:  K Harada; Y Sudo; N Kono; S Ozaki; K Tsuneyama; M E Gershwin; Y Nakanuma
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

5.  Comparative epitope mapping of murine monoclonal and human autoantibodies to human PDH-E2, the major mitochondrial autoantigen of primary biliary cirrhosis.

Authors:  C D Surh; A Ahmed-Ansari; M E Gershwin
Journal:  J Immunol       Date:  1990-04-01       Impact factor: 5.422

6.  Cryptic antigenic determinants on the extracellular pyruvate dehydrogenase complex/mimeotope found in primary biliary cirrhosis. A probe by affinity mass spectrometry.

Authors:  T T Yip; J Van de Water; M E Gershwin; R L Coppel; T W Hutchens
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

7.  Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody-negative primary biliary cirrhosis.

Authors:  K Tsuneyama; J Van De Water; D Van Thiel; R Coppel; B Ruebner; Y Nakanuma; E R Dickson; M E Gershwin
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

8.  PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis.

Authors:  Alessandro Granito; Wei-Hong Yang; Luigi Muratori; Mark J Lim; Ayako Nakajima; Silvia Ferri; Georgios Pappas; Chiara Quarneti; Francesco B Bianchi; Donald B Bloch; Paolo Muratori
Journal:  Am J Gastroenterol       Date:  2009-10-27       Impact factor: 10.864

9.  Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis.

Authors:  J Wesierska-Gadek; H Hohenuer; E Hitchman; E Penner
Journal:  Gastroenterology       Date:  1996-03       Impact factor: 22.682

10.  Diagnostic utility of IgG and IgM immunohistochemistry in autoimmune liver disease.

Authors:  Roger Klein Moreira; Frank Revetta; Elizabeth Koehler; Mary Kay Washington
Journal:  World J Gastroenterol       Date:  2010-01-28       Impact factor: 5.742

View more
  2 in total

Review 1.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

2.  Immunofluorescence identifies distinct subsets of endothelial cells in the human liver.

Authors:  Otto Strauss; Anthony Phillips; Katya Ruggiero; Adam Bartlett; P Rod Dunbar
Journal:  Sci Rep       Date:  2017-03-13       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.